ADPEN Laboratories

The Analytical Partner You Trust

  • ABOUT ADPEN
    • CORONAVIRUS UPDATE:
    • Our Staff
    • Our Facilities
    • Our Instrumentation
  • CONTACT ADPEN
    • Request Info or Quote
  • TEST REQUEST FORMS
  • RESOURCES
    • Analytical Services and Testing Brochures
    • Career Opportunities
    • Industry Guidance Documents
    • Terms and Conditions
  • AGROSCIENCES
    • ANALYTICAL TESTING
    • ECOTOX
    • 5-BATCH ANALYSIS
    • PRODUCT CHEMISTRY
  • PHARMACEUTICALS
    • CONTRACT FORMULATION AND MANUFACTURING
    • PHARMACEUTICAL TESTING
    • NITROSAMINE IMPURITIES IN PHARMACEUTICALS
  • FOOD SAFETY
    • NUTRITIONALS
    • FOOD SAFETY TESTING
  • ANIMAL HEALTH
You are here: Home / ALL NEWS / All Services / FDA Publishes Guidance on Marketed Unapproved Drugs

FDA Publishes Guidance on Marketed Unapproved Drugs

October 3, 2011 By Steven Perez

Last week, FDA published a guidance titled Marketed Unapproved Drugs—Compliance Policy Guide, which describes the agency’s enforcement priorities with regard to products that lack regulatory approval or that are not marketed in accordance with the over-the-counter (OTC) drug review. The document is a revision of the June 2006 guidance of the same name.

Because FDA lacks the resources to take immediate action against all illegally marketed products, it will give higher priority to enforcement actions that involve unapproved drug products in certain categories, including drugs with potential safety risks, and drugs that lack evidence of effectiveness.

Another high-priority category for FDA is health-fraud drugs. The guidance defines health fraud as “[t]he deceptive promotion, advertisement, distribution, or sale of articles . . . that are represented as being effective to diagnose, prevent, cure, treat, or mitigate disease (or other conditions), or provide a beneficial effect on health, but which have not been scientifically proven safe and effective for such purposes.” Drugs that present a direct risk to health will be the agency’s highest priority in this product category.

Read more about the FDA’s published guidance on marketed unapproved Drugs at PharmTech.com.

Filed Under: All Services, Analytical Testing News & Updates | ADPEN Laboratories, Pharmaceutical Links Tagged With: analysis, FDA, GMP, guidance, pharmaceuticals, Testing

ISO/IEC 17025 ACCREDITED

ISO/IEC 17025 is a company level accreditation based on a standard published by the International Organization for Standardization (ISO) titled “General requirements for the competence of testing and calibration laboratories”. ISO/IEC 17025 is a general umbrella term used to refer to the specific standard; the current version of this standard is ISO/IEC 17025:2017. The standard contains two main sections: management requirements (primarily related to the operation and effectiveness of the quality management system within the laboratory) and technical requirements (primarily related to the competence of staff and calibration of equipment). The standard also gives requirements related to quality management such as document control and corrective action. This standard is the basis for accreditation from an accrediting body.

ADPEN has also been inspected by the US-EPA and US-FDA multiple times with no observations.

Agroscience Links

  • 5-Batch Analytical Services
  • Analytical Testing Brochure
  • Pesticide Residue Analytical Services

Let’s Network!

Follow @AdpenLabs

RSS USEPA- Agriculture News

What Our Clients Say About ADPEN

“Congratulation for your success and your hard work. You literally completed the most complex method validation that I have seen…” M.S.

Get in Touch With Us

ADPEN Laboratories, Inc.
11757 Central Parkway
Jacksonville, FL 32224 USA

Phone: 1.904.645.9169
Fax: (904) 641-8423
Contact Form

Copyright © 2021 · Enterprise Pro Theme on Genesis Framework · WordPress · Log in